

Name of journal: World Journal of Hepatology

ESPS Manuscript NO: 15294

Columns: Original Article

Observational Study

Virological response and resistance mutations to NS3/4A inhibitors in HCV-HIV coinfection

Alissa Naqvi, Valérie Giordanengo, Brigitte Dunais, Francine de Salvador-Guillouet, Isabelle Perbost, Jacques Durant, Pascal Pugliese, Aline Joulié, Pierre Marie Roger, Eric Rosenthal; the COREVIH PACA-EST Group

Abstract

AIM: To evaluate virological response to telaprevir or boceprevir in combination with pegylated interferon and ribavirin and resistance mutations to NS3/4A inhibitors in HIV-HCV coinfectd patients in real life setting.

METHODS: Patients with HCV genotype 1-HIV coinfection followed in Nice University Hospital internal medicine and infectious diseases departments who initiated treatment including pegylated interferon and ribavirin (PegIFN/RBV) + telaprevir or boceprevir, according to standard treatment protocols, between August 2011 and October 2013 entered this observational study. Patient data were extracted from an electronic database (Nadis®). Liver fibrosis was measured by elastometry (Fibroscan®) with the following cut-off values: F0-F1: <7.1 kPa, F2: 7.1-9.5 kPa, F3: 9.5-14.5 kPa, F4: >14.5 kPa. The proportion of patients with sustained virological

Match Overview

There are no matching sources for this report.



Virological response and resistance mutations to NS3/4A inhibitors in HCV



网页

新闻

图片

视频

更多 ▾

搜索工具

找到约 16,300 条结果 (用时 0.79 秒)

Google 学术: Virological response and resistance mutations to NS3/4A inhibitors in HCV-HIV coinfection

The way forward in HCV treatment—finding the right ... - Manns - 被引用次数: 267

Current and future therapies for hepatitis C virus ... - Liang - 被引用次数: 188

Boceprevir for untreated chronic HCV genotype 1 ... - Poordad - 被引用次数: 2040

Complexity and Catalytic Efficiency of Hepatitis C Virus ...

www.ncbi.nlm.nih.gov > ... > PubMed Central (PMC) ▾ 翻译此页

作者: E Aparicio - 2011 - 被引用次数: 10 - 相关文章

The role of the hepatitis C virus (HCV) NS3/4A protease in ablating the signaling ... treatment response, as shown in our cohort of HIV-HCV-coinfected patients. and RBV with a known virologic response status at 24 weeks posttreatment. Mutations conferring resistance to NS3 protease inhibitors (PIs) were also found in ...

Hepatitis C and HIV Co-Infection: New Drugs in Practice and ...

www.ncbi.nlm.nih.gov > ... > PubMed Central (PMC) ▾ 翻译此页

作者: CL Jennings - 2012 - 被引用次数: 6 - 相关文章

The two HCV NS3/4A serine protease inhibitors (PIs), boceprevir (BOC) and telaprevir ... Patients were treated using a response-guided therapy (RGT) schema for the resistance mutations does not appear to be increased among HCV/HIV Sustained virologic response and boceprevir resistance-associated variants ...

Hepatitis C virus (HCV) protease variability and anti - HCV ...

onlinelibrary.wiley.com/doi/10.1111/j.1468-1293.2011../pdf - 翻译此页

作者: P Trimoulet - 2011 - 被引用次数: 19 - 相关文章

Data on the natural selection of isolates harbouring mutations within the NS3 protease, conferring resistance to hepatitis C virus (HCV) protease inhibitors (PIs), are limited for HIV/HCV- ... resistance to HCV PIs in HIV/HCV-coinfected patients compared with ... virological response in 35% of HIV/HCV genotype 1 or 4-.

Sustained Virologic Response to Antiviral Therapy for Chronic

cid.oxfordjournals.org/content/52/7/889.long ▾ 翻译此页

网页

新闻

图片

视频

更多 ▾

搜索工具

找到约 10,000 条结果 (用时 0.68 秒)

Google 学术: Virological response and resistance mutations to NS3/4A inhibitors in hepatitis C virus-human immunodeficiency virus coinfection

... ribavirin for chronic hepatitis C virus infection in HIV- ... - Torriani - 被引用次数: 1364
... the protease inhibitor BI 201335, polymerase inhibitor ... - Zeuzem - 被引用次数: 129
... plus ribavirin for chronic hepatitis C in HIV-coinfected ... - Chung - 被引用次数: 949

小提示: 仅限搜索简体中文结果。您可以在设置中指定搜索语言

Complexity and Catalytic Efficiency of Hepatitis C Virus (HCV)

www.ncbi.nlm.nih.gov > ... > [PubMed Central \(PMC\)](http://pubmed.ncbi.nlm.nih.gov) ▾ 翻译此页

作者: E Aparicio - 2011 - 被引用次数: 11 - 相关文章

The role of the hepatitis C virus (HCV) NS3/4A protease in ablating the signaling ...
treatment response, as shown in our cohort of HIV-HCV-coinfected patients. ... and RBV
with a known virologic response status at 24 weeks posttreatment. Mutations
conferring resistance to NS3 protease inhibitors (PIs) were also found in ...

Sustained Virologic Response to Antiviral Therapy for ...

cid.oxfordjournals.org/content/52/7/889.long ▾ 翻译此页

作者: BL Pearlman - 2011 - 被引用次数: 154 - 相关文章

More than 170 million persons worldwide are infected with hepatitis C virus (HCV)
Finally, clinical outcomes may also be diminished in SVR-achieving HIV-coinfected
that DAA monotherapy selects for resistance mutations rapidly [126–128]. of HCV trial
used 14-day regimens of the NS3/4A protease inhibitor R7227 ...

Hepatitis C virus (HCV) protease variability and antiHCV